Agios Pharmaceuticals, Inc.

Hua Yang

Samuel V Agresta

Yanfeng Zhang

Chong-Hui Gu

David Schenkein

Jianming Wang

Liting Guo

Zhen Tang

Yan Zhou

Lenny Dang

Chandra Agarwal Prakash

Charles Kung

Bruce A Silver

Leonard Luan C Dang

Marvin Barry Cohen

Varsha Venkatachalam Iyer

Elizabeth A Merica

Yue Chen

Marvin B Cohen

Bruce Alan Silver

Leonard Luan Dang

Described herein are methods of treating pyruvate kinase deficiency (PKD), sickle cell disease or thalassemia with mitapivat or a pharmaceutically acceptable salt thereof, or use of the drug for the treatment of these conditions, in combination with or in the absence of with a secondary drug, such as an inducer or an inhibitor of cytochrome P450. Various doses and dosing regimens of mitapivat in monotherapy and in concomitant medications are described.

Mitapivat therapy and modulators of cytochrome P450

Described herein are methods for using compounds that activate pyruvate kinase.

Methods of using pyruvate kinase activators

Provided are compounds useful for treating of cancer and methods for treating of cancer, comprising administering to a subject in need thereof a compound described therein.

Therapeutically active compounds and their methods of use

Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.

Provided are isocitrate dehydrogenase 2 (IDH2) inhibitor compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein. Also provided are polymorphic forms of the IDH2 inhibitor compounds characterized by X Ray powder diffraction patterns, having improved physicochemical properties that influence in vivo dissolution rate for formulation purposes.

Growing community of inventors

Acton, MA, United States of America

Hua Yang